DB05736ExperimentalSmall molecule
MIV-701 is a selective, potent inhibitor of the protease Cathepsin K. It is developed for the treatment of osteoporosis.
- Mechanism
- Curator reviewed
MIV-701 inhibits an enzyme, cathepsin K, which degrades bone, but most probably also contributes to cartilage damage in joint diseases. It greatly reduces degradation of bone.
- Primary indication
- Investigated for use/treatment in osteoporosis.Curator reviewed
- Code names
- MIV-701
Resolves to
Targets
What you can answer from here — as of April 02, 2025
1Protein targetEach mapped to UniProt, with action and pharmacological actionListed above
Which drugs share a target with MIV-701, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account